Datamonitor’s OTC Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry Guide is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry in Brazil, Hungary, Mexico, Poland, South Africa, and Taiwan. The report includes easily comparable data on market value, volume, segmentation and market share for the advanced emerging markets otc pharmaceuticals markets, plus full five-year market forecasts. It examines future problems, innovations and potential growth areas within the market.
Scope of the Report
* Contains an executive summary and data on value, volume and segmentation
* Provides textual analysis of the industry’s prospects, competitive landscape and profiles of the leading companies
* Incorporates in-depth five forces competitive environment analysis and scorecards
* Compares data from Brazil, Hungary, Mexico, Poland, South Africa and Taiwan, alongside individual chapters on each country. .
* Includes a five-year forecast of the industry
Highlights
The advanced emerging market countries contributed $8,059.5 million to the global otc pharmaceuticals industry in 2005, with a compound annual growth rate (CAGR) of 6.5% between 2005 and 2009 bringing this contribution to $10,370.4million.
These countries are expected to reach a value of $13,331.5 million in 2014, with a CAGR of 5.2% over the 2009–14 period.
Brazil holds the major share of the OTC pharmaceutical industry. In 2009, it accounted for 36.1% of the market.
Why you should buy this report
* Spot future trends and developments
* Inform your business decisions
* Add weight to presentations and marketing materials
* Save time carrying out entry-level research
Market Definition
The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness).
INTRODUCTION 14
What Is This Report About? 14
Who Is The Target Reader? 14
Definition 14
ADVANCED EMERGING MARKETS OTC PHARMACEUTICALS INDUSTRY OUTLOOK 15
OTC PHARMACEUTICALS IN BRAZIL 22
Market Overview 22
Market Value 23
Market Segmentation I 24
Market Segmentation Ii 25
Market Share 26
Five Forces Analysis 27
Leading Companies 35
Market Distribution 54
Market Forecasts 55
Macroeconomic Indicators 57
OTC PHARMACEUTICALS IN HUNGARY 59
Market Overview 59
Market Value 60
Market Segmentation I 61
Market Segmentation Ii 62
Market Share 63
Five Forces Analysis 64
Leading Companies 72
Market Distribution 83
Market Forecasts 84
Macroeconomic Indicators 86
OTC PHARMACEUTICALS IN MEXICO 88
Market Overview 88
Market Value 89
Market Segmentation I 90
Market Segmentation Ii 92
Market Share 93
Five Forces Analysis 94
Leading Companies 102
Market Distribution 121
Market Forecasts 122
Macroeconomic Indicators 124
OTC PHARMACEUTICALS IN POLAND 126
Market Overview 126
Market Value 127
Market Segmentation I 128
Market Segmentation Ii 129
Market Share 130
Five Forces Analysis 131
Leading Companies 139
Market Distribution 150
Market Forecasts 151
Macroeconomic Indicators 153
OTC PHARMACEUTICALS IN SOUTH AFRICA 155
Market Overview 155
Market Value 156
Market Segmentation I 157
Market Share 158
Five Forces Analysis 159
Leading Companies 167
Market Distribution 175
Market Forecasts 176
Macroeconomic Indicators 178
OTC PHARMACEUTICALS IN TAIWAN 180
Market Overview 180
Market Value 181
Market Segmentation I 182
Market Segmentation Ii 183
Market Share 184
Five Forces Analysis 185
Leading Companies 193
Market Distribution 209
Market Forecasts 210
Macroeconomic Indicators 212
APPENDIX 214
Data Research Methodology 214
About Datamonitor 215
Disclaimer 215
LIST OF TABLES
Table 1: Advanced emerging markets otc pharmaceuticals industry, revenue ($m), 2005–14 16
Table 2: Advanced emerging markets otc pharmaceuticals industry, revenue by country ($m), 2005–09 19
Table 3: Advanced emerging markets otc pharmaceuticals industry forecast, revenue by country ($m), 2009–14 21
Table 4: Brazil OTC pharmaceuticals market value: $ million, 2005–09 23
Table 5: Brazil OTC pharmaceuticals market segmentation I:% share, by value, 2009 24
Table 6: Brazil OTC pharmaceuticals market segmentation II: % share, by value, 2009 25
Table 7: Brazil OTC pharmaceuticals market share: % share, by value, 2009 26
Table 8: Johnson & Johnson: key facts 35
Table 9: Johnson & Johnson: key financials ($) 39
Table 10: Johnson & Johnson: key financial ratios 39
Table 11: Sanofi-Aventis: key facts 42
Table 12: Sanofi-Aventis: key financials ($) 45
Table 13: Sanofi-Aventis: key financials (€) 45
Table 14: Sanofi-Aventis: key financial ratios 46
Table 15: Abbott Laboratories: key facts 48
Table 16: Abbott Laboratories: key financials ($) 51
Table 17: Abbott Laboratories: key financial ratios 51
Table 18: Brazil OTC pharmaceuticals market distribution: % share, by value, 2009 54
Table 19: Brazil OTC pharmaceuticals market value forecast: $ million, 2009–14 55
Table 20: Brazil size of population (million), 2005–09 57
Table 21: Brazil gdp (constant 2000 prices, $ billion), 2005–09 57
Table 22: Brazil gdp (current prices, $ billion), 2005–09 57
Table 23: Brazil inflation, 2005–09 58
Table 24: Brazil consumer price index (absolute), 2005–09 58
Table 25: Brazil exchange rate, 2005–09 58
Table 26: Hungary OTC pharmaceuticals market value: $ million, 2005–09 60
Table 27: Hungary OTC pharmaceuticals market segmentation I:% share, by value, 2009 61
Table 28: Hungary OTC pharmaceuticals market segmentation II: % share, by value, 2009 62
Table 29: Hungary OTC pharmaceuticals market share: % share, by value, 2009 63
Table 30: Johnson & Johnson: key facts 72
Table 31: Johnson & Johnson: key financials ($) 75
Table 32: Johnson & Johnson: key financial ratios 75
Table 33: Béres Pharmaceuticals Co. Ltd: key facts 78
Table 34: EGIS Pharmaceuticals Ltd.: key facts 79
Table 35: EGIS Pharmaceuticals Ltd.: key financials ($) 80
Table 36: EGIS Pharmaceuticals Ltd.: key financials (HUF) 80
Table 37: EGIS Pharmaceuticals Ltd.: key financial ratios 81
Table 38: Hungary OTC pharmaceuticals market distribution: % share, by value, 2009 83
Table 39: Hungary OTC pharmaceuticals market value forecast: $ million, 2009–14 84
Table 40: Hungary size of population (million), 2005–09 86
Table 41: Hungary gdp (constant 2000 prices, $ billion), 2005–09 86
Table 42: Hungary gdp (current prices, $ billion), 2005–09 86
Table 43: Hungary inflation, 2005–09 87
Table 44: Hungary consumer price index (absolute), 2005–09 87
Table 45: Hungary exchange rate, 2005–09 87
Table 46: Mexico OTC pharmaceuticals market value: $ million, 2005–09 89
Table 47: Mexico OTC pharmaceuticals market segmentation I:% share, by value, 2009 90
Table 48: Mexico OTC pharmaceuticals market segmentation II: % share, by value, 2009 92
Table 49: Mexico OTC pharmaceuticals market share: % share, by value, 2009 93
Table 50: Bayer AG: key facts 102
Table 51: Bayer AG: key financials ($) 106
Table 52: Bayer AG: key financials (€) 106
Table 53: Bayer AG: key financial ratios 107
Table 54: Johnson & Johnson: key facts 109
Table 55: Johnson & Johnson: key financials ($) 112
Table 56: Johnson & Johnson: key financial ratios 112
Table 57: Boehringer Ingelheim GmbH: key facts 115
Table 58: Boehringer Ingelheim GmbH: key financials ($) 118
Table 59: Boehringer Ingelheim GmbH: key financials (€) 118
Table 60: Boehringer Ingelheim GmbH: key financial ratios 119
Table 61: Mexico OTC pharmaceuticals market distribution: % share, by value, 2009 121
Table 62: Mexico OTC pharmaceuticals market value forecast: $ million, 2009–14 122
Table 63: Mexico size of population (million), 2005–09 124
Table 64: Mexico gdp (constant 2000 prices, $ billion), 2005–09 124
Table 65: Mexico gdp (current prices, $ billion), 2005–09 124
Table 66: Mexico inflation, 2005–09 125
Table 67: Mexico consumer price index (absolute), 2005–09 125
Table 68: Mexico exchange rate, 2005–09 125
Table 69: Poland OTC pharmaceuticals market value: $ million, 2005–09 127
Table 70: Poland OTC pharmaceuticals market segmentation I:% share, by value, 2009 128
Table 71: Poland OTC pharmaceuticals market segmentation II: % share, by value, 2009 129
Table 72: Poland OTC pharmaceuticals market share: % share, by value, 2009 130
Table 73: GlaxoSmithKline Plc: key facts 139
Table 74: GlaxoSmithKline Plc: key financials ($) 143
Table 75: GlaxoSmithKline Plc: key financials (£) 143
Table 76: GlaxoSmithKline Plc: key financial ratios 144
Table 77: US Pharmacia: key facts 147
Table 78: Herbapol Wroclaw SA: key facts 149
Table 79: Poland OTC pharmaceuticals market distribution: % share, by value, 2009 150
Table 80: Poland OTC pharmaceuticals market value forecast: $ million, 2009–14 151
Table 81: Poland size of population (million), 2005–09 153
Table 82: Poland gdp (constant 2000 prices, $ billion), 2005–09 153
Table 83: Poland gdp (current prices, $ billion), 2005–09 153
Table 84: Poland inflation, 2005–09 154
Table 85: Poland consumer price index (absolute), 2005–09 154
Table 86: Poland exchange rate, 2005–09 154
Table 87: South Africa OTC pharmaceuticals market value: $ million, 2005–09 156
Table 88: South Africa OTC pharmaceuticals market segmentation I:% share, by value, 2009 157
Table 89: South Africa OTC pharmaceuticals market share: % share, by value, 2009 158
Table 90: Pharma Natura (Pty) Ltd: key facts 167
Table 91: Weleda Group: key facts 168
Table 92: Johnson & Johnson: key facts 169
Table 93: Johnson & Johnson: key financials ($) 172
Table 94: Johnson & Johnson: key financial ratios 172
Table 95: South Africa OTC pharmaceuticals market distribution: % share, by value, 2009 175
Table 96: South Africa OTC pharmaceuticals market value forecast: $ million, 2009–14 176
Table 97: South Africa size of population (million), 2005–09 178
Table 98: South Africa gdp (constant 2000 prices, $ billion), 2005–09 178
Table 99: South Africa gdp (current prices, $ billion), 2005–09 178
Table 100: South Africa inflation, 2005–09 179
Table 101: South Africa consumer price index (absolute), 2005–09 179
Table 102: South Africa exchange rate, 2005–09 179
Table 103: Taiwan OTC pharmaceuticals market value: $ million, 2005–09 181
Table 104: Taiwan OTC pharmaceuticals market segmentation I:% share, by value, 2009 182
Table 105: Taiwan OTC pharmaceuticals market segmentation II: % share, by value, 2009 183
Table 106: Taiwan OTC pharmaceuticals market share: % share, by value, 2009 184
Table 107: China Chemical and Pharmaceutical Co., Ltd.: key facts 193
Table 108: China Chemical and Pharmaceutical Co., Ltd.: key financials ($) 195
Table 109: China Chemical and Pharmaceutical Co., Ltd.: key financials (NT$) 195
Table 110: China Chemical and Pharmaceutical Co., Ltd.: key financial ratios 196
Table 111: Sinphar pharmaceuticals co ltd: key facts 199
Table 112: Sinphar pharmaceuticals co ltd: key financials ($) 201
Table 113: Sinphar pharmaceuticals co ltd: key financials (NT$) 201
Table 114: Sinphar pharmaceuticals co ltd: key financial ratios 202
Table 115: Daiichi Sankyo, Ltd.: key facts 204
Table 116: Daiichi Sankyo, Ltd.: key financials ($) 206
Table 117: Daiichi Sankyo, Ltd.: key financials (¥) 206
Table 118: Daiichi Sankyo, Ltd.: key financial ratios 207
Table 119: Taiwan OTC pharmaceuticals market distribution: % share, by value, 2009 209
Table 120: Taiwan OTC pharmaceuticals market value forecast: $ million, 2009–14 210
Table 121: Taiwan size of population (million), 2005–09 212
Table 122: Taiwan gdp (constant 2000 prices, $ billion), 2005–09 212
Table 123: Taiwan gdp (current prices, $ billion), 2005–09 212
Table 124: Taiwan inflation, 2005–09 213
Table 125: Taiwan consumer price index (absolute), 2005–09 213
Table 126: Taiwan exchange rate, 2005–09 213
LIST OF FIGURES
Figure 1: Advanced emerging markets otc pharmaceuticals industry, revenue ($m), 2005–14 15
Figure 2: Advanced emerging markets otc pharmaceuticals industry, country analysis (%), 2005–14 17
Figure 3: Advanced emerging markets otc pharmaceuticals industry, revenue by country ($m), 2005–09 18
Figure 4: Advanced emerging markets otc pharmaceuticals industry forecast, revenue by country ($m), 2009–14 20
Figure 5: Brazil OTC pharmaceuticals market value: $ million, 2005–09 23
Figure 6: Brazil OTC pharmaceuticals market segmentation I:% share, by value, 2009 24
Figure 7: Brazil OTC pharmaceuticals market segmentation II: % share, by value, 2009 25
Figure 8: Brazil OTC pharmaceuticals market share: % share, by value, 2009 26
Figure 9: Forces driving competition in the OTC pharmaceuticals market in Brazil, 2009 27
Figure 10: Drivers of buyer power in the OTC pharmaceuticals market in Brazil, 2009 29
Figure 11: Drivers of supplier power in the OTC pharmaceuticals market in Brazil, 2009 30
Figure 12: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Brazil, 2009 31
Figure 13: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Brazil, 2009 33
Figure 14: Drivers of degree of rivalry in the OTC pharmaceuticals market in Brazil, 2009 34
Figure 15: Johnson & Johnson: revenues & profitability 40
Figure 16: Johnson & Johnson: assets & liabilities 41
Figure 17: Sanofi-Aventis: revenues & profitability 46
Figure 18: Sanofi-Aventis: assets & liabilities 47
Figure 19: Abbott Laboratories: revenues & profitability 52
Figure 20: Abbott Laboratories: assets & liabilities 53
Figure 21: Brazil OTC pharmaceuticals market distribution: % share, by value, 2009 54
Figure 22: Brazil OTC pharmaceuticals market value forecast: $ million, 2009–14 56
Figure 23: Hungary OTC pharmaceuticals market value: $ million, 2005–09 60
Figure 24: Hungary OTC pharmaceuticals market segmentation I:% share, by value, 2009 61
Figure 25: Hungary OTC pharmaceuticals market segmentation II: % share, by value, 2009 62
Figure 26: Hungary OTC pharmaceuticals market share: % share, by value, 2009 63
Figure 27: Forces driving competition in the OTC pharmaceuticals market in Hungary, 2009 64
Figure 28: Drivers of buyer power in the OTC pharmaceuticals market in Hungary, 2009 66
Figure 29: Drivers of supplier power in the OTC pharmaceuticals market in Hungary, 2009 67
Figure 30: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Hungary, 2009 68
Figure 31: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Hungary, 2009 70
Figure 32: Drivers of degree of rivalry in the OTC pharmaceuticals market in Hungary, 2009 71
Figure 33: Johnson & Johnson: revenues & profitability 76
Figure 34: Johnson & Johnson: assets & liabilities 77
Figure 35: EGIS Pharmaceuticals Ltd.: revenues & profitability 81
Figure 36: EGIS Pharmaceuticals Ltd.: assets & liabilities 82
Figure 37: Hungary OTC pharmaceuticals market distribution: % share, by value, 2009 83
Figure 38: Hungary OTC pharmaceuticals market value forecast: $ million, 2009–14 85
Figure 39: Mexico OTC pharmaceuticals market value: $ million, 2005–09 89
Figure 40: Mexico OTC pharmaceuticals market segmentation I:% share, by value, 2009 91
Figure 41: Mexico OTC pharmaceuticals market segmentation II: % share, by value, 2009 92
Figure 42: Mexico OTC pharmaceuticals market share: % share, by value, 2009 93
Figure 43: Forces driving competition in the OTC pharmaceuticals market in Mexico, 2009 94
Figure 44: Drivers of buyer power in the OTC pharmaceuticals market in Mexico, 2009 96
Figure 45: Drivers of supplier power in the OTC pharmaceuticals market in Mexico, 2009 97
Figure 46: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Mexico, 2009 98
Figure 47: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Mexico, 2009 100
Figure 48: Drivers of degree of rivalry in the OTC pharmaceuticals market in Mexico, 2009 101
Figure 49: Bayer AG: revenues & profitability 107
Figure 50: Bayer AG: assets & liabilities 108
Figure 51: Johnson & Johnson: revenues & profitability 113
Figure 52: Johnson & Johnson: assets & liabilities 114
Figure 53: Boehringer Ingelheim GmbH: revenues & profitability 119
Figure 54: Boehringer Ingelheim GmbH: assets & liabilities 120
Figure 55: Mexico OTC pharmaceuticals market distribution: % share, by value, 2009 121
Figure 56: Mexico OTC pharmaceuticals market value forecast: $ million, 2009–14 123
Figure 57: Poland OTC pharmaceuticals market value: $ million, 2005–09 127
Figure 58: Poland OTC pharmaceuticals market segmentation I:% share, by value, 2009 128
Figure 59: Poland OTC pharmaceuticals market segmentation II: % share, by value, 2009 129
Figure 60: Poland OTC pharmaceuticals market share: % share, by value, 2009 130
Figure 61: Forces driving competition in the OTC pharmaceuticals market in Poland, 2009 131
Figure 62: Drivers of buyer power in the OTC pharmaceuticals market in Poland, 2009 133
Figure 63: Drivers of supplier power in the OTC pharmaceuticals market in Poland, 2009 134
Figure 64: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Poland, 2009 135
Figure 65: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Poland, 2009 137
Figure 66: Drivers of degree of rivalry in the OTC pharmaceuticals market in Poland, 2009 138
Figure 67: GlaxoSmithKline Plc: revenues & profitability 145
Figure 68: GlaxoSmithKline Plc: assets & liabilities 146
Figure 69: Poland OTC pharmaceuticals market distribution: % share, by value, 2009 150
Figure 70: Poland OTC pharmaceuticals market value forecast: $ million, 2009–14 152
Figure 71: South Africa OTC pharmaceuticals market value: $ million, 2005–09 156
Figure 72: South Africa OTC pharmaceuticals market segmentation I:% share, by value, 2009 157
Figure 73: South Africa OTC pharmaceuticals market share: % share, by value, 2009 158
Figure 74: Forces driving competition in the OTC pharmaceuticals market in South Africa, 2009 159
Figure 75: Drivers of buyer power in the OTC pharmaceuticals market in South Africa, 2009 161
Figure 76: Drivers of supplier power in the OTC pharmaceuticals market in South Africa, 2009 162
Figure 77: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in South Africa, 2009 163
Figure 78: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in South Africa, 2009 165
Figure 79: Drivers of degree of rivalry in the OTC pharmaceuticals market in South Africa, 2009 166
Figure 80: Johnson & Johnson: revenues & profitability 173
Figure 81: Johnson & Johnson: assets & liabilities 174
Figure 82: South Africa OTC pharmaceuticals market distribution: % share, by value, 2009 175
Figure 83: South Africa OTC pharmaceuticals market value forecast: $ million, 2009–14 177
Figure 84: Taiwan OTC pharmaceuticals market value: $ million, 2005–09 181
Figure 85: Taiwan OTC pharmaceuticals market segmentation I:% share, by value, 2009 182
Figure 86: Taiwan OTC pharmaceuticals market segmentation II: % share, by value, 2009 183
Figure 87: Taiwan OTC pharmaceuticals market share: % share, by value, 2009 184
Figure 88: Forces driving competition in the OTC pharmaceuticals market in Taiwan, 2009 185
Figure 89: Drivers of buyer power in the OTC pharmaceuticals market in Taiwan, 2009 187
Figure 90: Drivers of supplier power in the OTC pharmaceuticals market in Taiwan, 2009 188
Figure 91: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Taiwan, 2009 189
Figure 92: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Taiwan, 2009 191
Figure 93: Drivers of degree of rivalry in the OTC pharmaceuticals market in Taiwan, 2009 192
Figure 94: China Chemical and Pharmaceutical Co., Ltd.: revenues & profitability 197
Figure 95: China Chemical and Pharmaceutical Co., Ltd.: assets & liabilities 198
Figure 96: Sinphar pharmaceuticals co ltd: revenues & profitability 202
Figure 97: Sinphar pharmaceuticals co ltd: assets & liabilities 203
Figure 98: Daiichi Sankyo, Ltd.: revenues & profitability 207
Figure 99: Daiichi Sankyo, Ltd.: assets & liabilities 208
Figure 100: Taiwan OTC pharmaceuticals market distribution: % share, by value, 2009 209
Figure 101: Taiwan OTC pharmaceuticals market value forecast: $ million, 2009–14 211
Other selected research from the 'OTC' category:
Personal Hygiene/ Personal Care: China Industry Guide
Personal Hygiene/ Personal Care: France Industry Guide